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Abstract
Patients without cytoreductive nephrectomy (CN) are inadequately represented in metastatic renal cell carcinoma (RCC) clinical trials. The 
characteristics that impact the decision of CN were explored in the SEER database. Data on primary, regional, or distant (metastatic) stage kid-
ney cancer over the period 2000–2013 were extracted from the National Cancer Institute Surveillance, Epidemiology, and End Results Program 
(SEER-18) database. A sub-analysis of Metropolitan Detroit cases, to evaluate the influence of comorbidities, was conducted. Logistic regression 
was used to calculate the odds ratios, and Cox model was used to calculate hazard ratios; 37% of 21,052 metastatic RCC cases had CN performed. 
CN demonstrated significant survival advantage (HR = 0.31, 95% confidence interval [CI]: 0.30–0.33). Comorbidity data were available on 76% 
of distant RCC cases from the Detroit SEER database. Neither hypertension, diabetes mellitus nor the number of comorbidities (0, 1 or 2) had a 
statistically significant impact on the likelihood of CN. Majority of patients (63%) with distant-stage RCC do not undergo CN and have a median 
overall survival (OS) of 3 months as compared to a median OS of 18 months for patients who have undergone CN. Patient demographics and 
tumor characteristics make a significant impact on the incidence of CN. The impact of comorbidities (number and type) was modest and not 
statistically significant. The optimal management of patients with synchronous primary and metastatic RCC needs to be prospectively evaluated 
in the setting of contemporary systemic therapy.
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Introduction
Cytoreductive nephrectomy (CN) in the presence of  meta-
static disease is a unique feature of  the therapeutics of  ad-
vanced renal cancer (RCC). There are two randomized trials 
demonstrating the overall survival (OS) benefit favoring 
CN in metastatic disease compared to systemic interferon 
therapy alone (1, 2). The only systemic therapies available 
previously were cytokine-based regimens such as interleukin 
and interferon during the time period when these CN trials 
were conducted. Within the last decade, 10 additional ther-
apies have attained Food and Drug Administration (FDA) 
approval in metastatic renal cancer (3). Until recently, no 
prospective study had been completed evaluating the role of 
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CN in the setting of  contemporary systemic therapies. The 
results of  two randomized trials comparing CN followed by 
sunitinib versus systemic therapy with sunitinib followed by 
CN [SURTIME trial] and nephrectomy followed by suni-
tinib versus sunitinib alone (CARMENA) were recently 
reported. Both studies indicated that the clinical outcomes 
with sunitinib alone were at least similar and possibly slightly 
improved in the metastatic RCC patients randomized to de-
ferred or no CN (4, 5). The studies showed that CN does not 
impart additional survival benefit in the setting of  effective 
systemic therapy, and a proportion of  patients are deprived 
of  systemic therapy due to complications of  CN. In sum-
mary, the concept of  CN being an essential component of 
metastatic RCC therapy is being seriously questioned. These 
data need to be considered in future therapeutic decisions in 
metastatic RCC.
The National Cancer Database (NCDB), which reflects 
community-based data from hospitals with Commission on 
Cancer accreditation, continues to reveal that the incidence 
of CN in distant-/advanced-stage RCC is seen in about a 
third of the patients (6). Unlike clinical trials of systemic 
therapy, where 80–100% of patients are receiving nephrec-
tomy, the majority of the patients in the real-world treatment 
of RCC are not receiving CN as primary management. The 
overall survival outcome has improved in advanced RCC; 
however, it also appears that the patients with CN received 
the maximum benefit (7). Despite randomized evidence to 
the contrary, the OS results in SEER show that CN patients 
have a large magnitude of benefit as compared to non-CN 
patients. This finding may be confounded by the fact that the 
patients undergoing CN are probably younger, healthier, and 
less likely to have aggressive or poor risk disease, factors that 
portend an improved prognosis regardless of nephrectomy 
status. In an attempt to overcome the confounding effect of 
conflicting prognostic factors, we analyzed and reported on 
a clinical trial population with metastatic disease and found 
that CN maintained a significant positive impact on clinical 
outcomes (8).
In the targeted therapy era, we conducted a SEER data 
analysis of outcomes in patients who have undergone CN 
versus those who have not undergone CN. The results re-
vealed that only the post-nephrectomy population appeared 
to benefit from advances in systemic therapies (8). Clearly, 
an intervention that would increase the possibility of CN in 
metastatic RCC would likely improve outcomes. The contro-
versy of whether CN should be standard in metastatic RCC 
continues, with the recent randomized prospective trials sug-
gesting minimal contribution of CN in improving outcomes 
in metastatic RCC. In addition, there is an added nuance of 
analyzing the role of CN in the presence of contemporary 
immune checkpoint combination therapy. There is preclin-
ical evidence that suggests that the immune checkpoint in-
hibitors would be primed to demonstrate improved efficacy 
in the presence of the primary tumor. Randomized trials of 
systemic therapy with immune checkpoint inhibition with or 
without CN are being planned in this setting.
We attempted to evaluate the magnitude of the problem 
by assessing the incidence of CN in metastatic RCC within 
the SEER data. We analyzed the factors that are likely to 
impact the decision of CN in the initial management of ad-
vanced RCC. We explored demographic and disease-related 
factors. In addition, we assessed the impact of comorbidi-
ties in receipt of initial CN using additional data from the 
 Metropolitan Detroit Cancer Surveillance System (MDCSS). 
We conducted an analysis of distant/metastatic cases of RCC 
within the SEER-18 data between 2000 and 2013. The inten-
tion was to evaluate the incidence of CN in the contemporary 
systemic therapy era and to assess the factors that impacted 
the decision of CN. We chose to explore the impact of a few 
key comorbidities such as renal function, hypertension, dia-
betes mellitus, and lung disease.
Methods
The National Cancer Institute Surveillance, Epidemiology, 
and End Results Program (SEER-18) contains regional re-
search data (1973–2011) submitted in November 2013 with 
the Katrina/Rita population adjustment, collected from 18 
American cancer registries, chosen for their data quality 
and population diversity. The MDCSS is a data contrib-
utor to the SEER Program. Data for the primary analyses 
were extracted using SEER*Stat software (version 8.3.1), 
for patients diagnosed with renal cancer between the years 
2000 and 2013. We restricted the analysis to the first diag-
nosis of  regional or distant stage kidney cancer, overall re-
ferred to as “metastatic” kidney cancer. Site-specific surgery 
codes 30, 40, 50, 70, or 80 were defined as having received 
nephrectomy. The main focus was advanced or metastatic 
cases with RCC which are coded as “distant” in SEER. 
 Logistic regression analysis was used to calculate odds ra-
tios (OR) of  a patient who has undergone nephrectomy, 
adjusted for age at diagnosis, race, gender, marital status, 
 insurance and disease histology, and grade. Cox propor-
tional hazards regression analysis was used to calculate 
adjusted hazard ratios (HR) to estimate the overall risk 
of  death. Hazard ratios were adjusted for nephrectomy as 
well as for all other variables listed above. Analyses were 
conducted using SAS software version 9.4 (SAS Institute 
Inc., Cary, NC). Patients with OS < 1 month were excluded 
from the analysis with the assumption that any treatment 
would not have a chance to impact their outcomes. Figure 1 
 depicts the flowchart of  the patient population considered 
and selected for analysis.
We also performed a separate analysis using the same 
criteria for MDCSS data, extracted from the local SEER 
 Database Management System (SEER*DMS) using SAS© 
v 9.4, to evaluate the influence of comorbidities, as these data 
are not collected by SEER. Logistic regression was used to 
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calculate the odds ratios for receiving CN. Hazard ratios were 
calculated using Cox proportional hazards regression.
Results
Overview and predictors of nephrectomy
After exclusion of renal pelvis cases, final SEER-18 data for 
2000–2013 had N = 40,524 patients. Case distribution by 
stage included regional stage (N = 19,472, 48%, 93% had 
nephrectomy) and distant stage (N = 21,052, 52%, 37% had 
nephrectomy). Our analyses were restricted to distant or met-
astatic stage patients only (Figure 1). The population charac-
teristics of all SEER registry “regional” and “distant cases” 
are depicted in Table 1.
Adjusted predictors of statistically increased likelihood 
of receiving nephrectomy were age (≤63 years), male sex 
(white race), and marital status. An interaction effect was 
noted  between gender and marital status with married males 
having a significantly higher nephrectomy rate (42%) than 
divorced, single, and widowed men (35, 38, and 18% respec-
tively). Single males were significantly less likely to receive ne-
phrectomy than females (OR 0.53, 95% confidence interval 
[CI] 0.44–0.64). Single females had the highest (44%) likeli-
hood of nephrectomy. Non-clear cell histology and poorly 
differentiated grade had a higher possibility of receiving CN 
as compared to clear cell histology and well-differentiated 
cancer, respectively (Table 2).
Survival status
Receipt of nephrectomy demonstrated significant survival 
advantage (HR = 0.31, 95% CI: 0.30–0.33) in the adjusted 
hazards ratio model. Median OS was 3 months in the 
non-CN group and 18 months in the CN group (Table 3 and 
 Figure 2A). The demographic predictors of improved survival 
were age <63, white race, married status, and insured status 
(Table 3). Clear cell histology (HR = 1.20, 95% CI: 1.16–1.24) 
and well-differentiated grade are the disease-related charac-
teristics that portend for improved OS (Figure 2B). The lat-
ter demonstrated improved OS despite a lower, 43% CN rate 
as compared to 84% in the undifferentiated histology group. 
The histology grades in SEER of well, moderate, poor, and 
undifferentiated RCC are likely to be concordant with the 
conventional Fuhrman 1–4 grading (Table 3).
Comorbidity analyses in Metro Detroit Registry
The data regarding comorbid conditions were only available 
for the Metro Detroit (MDCSS) Registry. While not collected 
as a population-based variable, comorbidity status was coded 
for 82% of regional and 76% of metastatic kidney cancers 
seen in Metropolitan Detroit. Nephrectomy was performed in 
92% of regional stage and 34% of distant stage patients; our 
analysis pertains to only the distant-stage patients. Dichoto-
mous comorbidities (yes or no for: hypertension, cardiac dis-
ease, diabetes mellitus, kidney disease, and lung disease) and 
number of comorbid conditions (none, 1, 2, 3+, and miss-
ing) are included in the patient characteristics of MDSCC 
(Table 4). The demographic and tumor characteristics were 
concordant with the all SEER data; 44.9% of the patients 
had none of the comorbidities. Adjusted demographic pre-
dictors of increased likelihood of receiving nephrectomy for 
Metropolitan Detroit patients were age < 64 years, non-black 
race, and married status. Non-clear cell histology (OR = 
2.16, 95% CI: 1.42–3.28) and undifferentiated or high also 
predicted a higher likelihood of CN. Adding comorbidities 
and number of comorbidities to the model did not impact 
the likelihood of receiving nephrectomy. All comorbidity 
types and numbers were not statistically significant in terms 
of predicting the likelihood of CN and OS (Table 5). Patients 
with hypertension (OR = 1.75, 95% CI: 0.63–4.87) or diabe-
tes mellitus had greater likelihood of receiving nephrectomy 
(OR = 1.16, 95% CI: 0.42, 3.21). The group of patients with 
missing comorbidity data (261/1104, 23.6%) had a signifi-
cantly shorter OS in both CN and non-CN categories. The 
actual correlation of comorbidities with likelihood of CN 
remains elusive due to the group with missing data con-
stituting 24% of the population; 26% of this group had a 
Figure 1: Consort diagram of patient population included 
in analyses.
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Table 1: Population Characteristics and Nephrectomy Rates of All SEER Kidney Cancer, Regional or Distant Stage: 2000–2013.
Regional 18,837 Distant 18,422
N
Distribution 
(%)
Nephr  
Rate (%)
N
Distribution 
(%)
Nephr  
Rate (%)
Registry
Alaska 22 0 91 28 0 32
Atlanta 540 3 92 558 3 41
California (excl SF,SJM, & LA) 4196 22 94 4195 23 43
Connecticut 869 5 93 794 4 37
Detroit 939 5 93 947 5 39
Georgia (greater) 1381 7 92 1307 7 39
Hawaii 356 2 98 276 1 45
Iowa 896 5 96 921 5 43
Kentucky 1234 7 94 1184 6 43
Los Angeles 1845 10 95 1830 10 45
Louisiana 1370 7 91 1334 7 38
New Jersey 1985 11 94 1849 10 41
New Mexico 538 3 91 522 3 33
Rural Georgia 32 0 97 37 0 35
San Francisco 779 4 93 848 5 45
San Jose 421 2 95 448 2 43
Seattle 977 5 94 980 5 42
Utah 457 2 95 364 2 50
Age at diagnosis (year)
Under 20 626 3 98 502 3 91
20–39 577 3 96 452 2 55
40–49 1937 10 97 1855 10 56
50–59 4422 23 97 4511 24 51
60–69 5369 29 95 5184 28 42
70–79 4122 22 93 3762 20 31
80 or older 1784 9 78 2156 12 12
Sex
Female 6280 33 92 6185 34 39
Male 12,557 67 95 12,237 66 43
Race
Black 1612 9 90 1926 10 35
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Table 1 (Continued): Population Characteristics and Nephrectomy Rates of All SEER Kidney Cancer, Regional or Distant 
Stage: 2000–2013.
Regional 18,837 Distant 18,422
N
Distribution 
(%)
Nephr  
Rate (%)
N
Distribution 
(%)
Nephr  
Rate (%)
White 16,020 85 94 15,241 83 42
Other 1102 6 96 1208 7 44
Unknown 103 1 98 47 0 40
Marital status
Married 11,556 61 96 10,482 57 46
Divorced 1700 9 92 1994 11 39
Single 2959 16 95 3077 17 45
Widowed 1890 10 85 2230 12 22
Unknown 732 4 85 639 3 33
Insurance
Insured 8449 45 95 7573 41 43
Uninsured/medicaid 1530 8 93 1887 10 36
Unknown/missing 8858 47 93 8962 49 41
Histology
Clear cell 14,287 76 94 13,952 76 39
Renal cell carcinoma, Chromophobe 662 4 98 125 1 76
Renal cell carcinoma, Sarcomatoid 488 3 95 878 5 62
Collecting duct carcinoma 90 0 94 98 1 67
Papillary carcinoma, Oxyphilic cell 0 0 - 1 0 100
Other non-clear cell 3310 18 93 3368 18 46
Grade
Well differentiated 859 5 97 318 2 45
Moderately differentiated 5513 29 99 1750 9 71
Poorly differentiated 5902 31 98 3653 20 73
Undifferentiated 2319 12 98 2233 12 86
Unknown 4244 23 78 10,468 57 16
Surgery
Nephrectomy 17,665 94 7660 42
Other surgery 142 1 179 1
No urgery 1016 5 10,500 57
Unknown if  Surgery done 14 0 83 0
Nephr Rate, nephrectomy rate.
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Table 2: All SEER Distant Stage Kidney Cancer: 2000–2013; Odd Ratios for Likelihood of Nephrectomy.
Total N 18422
Nephr. Rate 
42 (%)
Unadjusted 
OR
Adjusted 
OR
95% CI p-value
Age at Diagnosis Diagnosis (median 63)
(ref) Under 63 8982 53 1.00 1.00
63 or Older 9440 31 0.39 0.41 (0.38–0.44) <0.001
Race (47 missing)
(ref) Black 1926 35 1.00 1.00
White 15241 42 1.34 1.51 (1.33–1.72) <0.001
Other 1208 44 1.43 1.52 (1.25–1.84) <0.001
Unknown 47 40 N/A
Insurance
(ref) Insured 7573 43 1.00 1.00
Medicaid or Uninsured 1887 36 0.75 0.65 (0.57–0.75) <0.001
Unknown or Missing 8962 41 0.93 1.17 (1.08–1.27) <0.001
Histology
(ref) Clear Cell 13952 39 1.00 1.00
Non-Clear Cell 4470 50 1.59 1.58 (1.45–1.73) <0.001
Grade
(ref) Well differentiated 318 45 1.00 1.00
Moderately differentiated 1750 71 3.06 3.35 (2.59–4.33) <0 001
Poorly differentiated 3653 73 3.32 3.24 (2.53–4.13) <0 001
Undifferentiated 2233 86 7.54 7.15 (5.49–9.31) <0 001
Unknown 10468 16 0.24 0.23 (0.18–0.29) <0 001
Sex
(ref) Female 6185 39 1.00
See interaction below
Male 12237 43 1.16
Marital Status
(ref) Married 10482 46 1.00
See interaction below
Divorced 1994 39 0.75
Single 3077 45 0.96
Widowed 2230 22 0.34
Unknown 639 33 0.58
Sex by Marital Status
Married
(ref) Female 2715 46 1.00 1.00
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Table 2 (Continued): All SEER Distant Stage Kidney Cancer: 2000–2013; Odd Ratios for Likelihood of Nephrectomy.
Total N 18422
Nephr. Rate 
42 (%)
Unadjusted 
OR
Adjusted 
OR
95% CI p-value
Male 7767 46 1.00 1.03 (0.92–1.16) 0.567
Divorced
(ref) Female 742 40 1.00 1.00
Male 1252 38 0.93 0.79 (0.62–1.00) 0.047
Single
(ref) Female 984 49 1.00 1.00
Male 2093 43 0.76 0.53 (0.44–0.64) <0.001
Widowed
(ref) Female 1528 22 1.00 1.00
Male 702 23 1.03 1.03 (0.79–1.34) 0.963
Unknown
(ref) Female 216 28 1.00 1.00
Male 423 35 1.43 1.33 (0.84–2.09) 0.298
Italic values represent missing data.
nephrectomy and demonstrated a median OS of 8 months as 
compared to the 76% with a median OS of 2 months (Tables 
4 and 5; Figure 3A and 3B).
Discussion
Our analysis reveals that CN is not being conducted in the 
majority of patients that present with synchronous meta-
static RCC. There is a tremendous discordance between the 
population of advanced RCC enrolled in prospective inter-
ventional clinical trials in which 80–90% of the patients have 
had nephrectomy, and the application of these reported ef-
ficacy data to clinical practice in which the majority of pa-
tients do not undergo CN. There is a discrepancy between 
the results of retrospective population-based data such as 
the SEER cancer registry outcomes data and the IMDC 
registry data in which OS is significantly better with CN, 
and those seen in prospective randomized trial results such 
as the CARMENA and SURTIME studies that show that 
CN is unlikely to make an impact on improving outcomes 
in the setting of contemporary anti-VEGF therapy such as 
sunitinib (9). SEER data consistently demonstrate that lack 
of CN is the largest contributor of shorter OS in RCC pa-
tients with distant-stage RCC. The factors included within 
the IMDC are not captured within the SEER database, and 
hence, comparison of patients within these different registries 
is not possible. However, it is highly likely that the extent of 
the impact of each factor on OS may not be equal, and inter-
action between the factors is likely. In addition, it is possible 
that synchronous presentation of primary kidney tumor and 
metastases represents a distinct disease entity than the pre-
sentation with metastatic disease following a remote history 
of nephrectomy (>12 months) for localized renal cancer.
The advent of immune therapy with checkpoint inhibitors 
has introduced a new perspective to the sequencing of CN and 
systemic therapy in metastatic RCC. Preclinical data continue 
to emerge supporting the optimal use of immune checkpoint 
inhibition with the primary tumor in place, due to higher mu-
tation load, increased heterogeneity of mutations and greater 
potential for anti-tumor CD8 T cells expansion and cytokine 
release (10, 11). These findings demand a deeper evaluation 
of the established paradigm of initial CN in metastatic RCC 
followed by systemic therapy. In fact, this standard is already 
being questioned in localized RCC by the current cooperative 
group trial EA8143/PROSPER, which randomizes patients 
to standard therapy of CN or neoadjuvant PD-1 inhibitor 
therapy with nivolumab followed by CN. In the metastatic 
disease also, deferral of nephrectomy as a potential method 
of enhancing the efficacy of immune checkpoint inhibition 
needs to be prospectively evaluated. SEER-18 limited use 
data do not include systemic agents, and this was a limitation 
of our analysis. A Southwest Oncology Group trial, S1931, 
is proposing to evaluate immune checkpoint inhibitor-based 
regimen combination with or without the addition of CN. 
The timing of surgery in the nephrectomy arm will be at the 
end of 12 weeks of immune therapy to optimize the impact 
of systemic therapy. The study design is that of a randomized 
phase III with overall survival as the primary endpoint.
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Table 3: All SEER Distant Stage Kidney Cancer (2000–2013) Survival Analysis (Median Survival, Adjusted Hazard Ratio, 95% 
Confidence Interval, and P-value).
Total
N 
18422
Median Survival (months)
HR 95% CI p-valueNephr. 
18
No Nephr. 
5
Age at Diagnosis (median 63)
(ref) Under 63 8982 20 25 1.00
63 or Older 9440 16 4 1.16 (1.12–1.20) <0.001
Sex
(ref) Female 6185 18 4 1.00
Male 12237 19 5 0.99 (0.96–1.03) 0.702
Race (47 missing)
(ref) Black 1926 16 4 1.00
White 15241 25 5 0.98 (0.93–1.02) 0.342
Other 1208 18 5 0.88 (0.81–0.95) 0.002
Marital Status
(ref) Married 10482 17 5 1.00
Divorced 1994 16 5 1.05 (1.00–1.11) 0.051
Single 3077 29 5 0.86 (0.82–0.90) <0.001
Widowed 2230 14 4 1.09 (1.04–1.15) 0.001
Unknown 639 20 5 0.86 (0.79–0.94) 0.001
Insurance
(ref) Insured 7573 20 5 1.00
Medicaid or Uninsured 1887 21 5 1.03 (0.97–1.09) 0.427
Unknown or Missing 8962 16 4 1.16 (1.12–1.20) 0.001
Histology
(ref) Clear Cell 13952 20 5 1.00
Non-Clear Cell 4470 13 4 1.16 (1.12–1.21) <0.001
Grade
(ref) Well differentiated 318 35 9 1.00
Moderately differentiated 1750 30 6 1.30 (1.13–1.49) <0.001
Poorly differentiated 3653 18 4 1.86 (1.63–2.13) <0.001
Undifferentiated 2233 11 3 2.47 (2.16–2.83) <0.001
Unknown 10468 26 5 1.48 (1.30–1.69) <0.001
Surgery
No Nephrectomy 10762 - 5 1.00
Nephrectomy 7660 18 - 0.34 (0.32–0.35) <0.001
95% CI, 95% confidence interval; HR, hazard ratio; Nephr, nephrectomy.
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Figure 2: (A) Overall survival data for nephrectomy or non-nephrectomy patients with advanced kidney cancer in SEER data-
base. (B) Overall survival outcomes in metastatic RCC by clear and non-clear histology with or without nephrectomy. 
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Conclusions
National population registry represented by the SEER 
database shows that the majority of  patients (63%) with 
metastatic RCC do not undergo CN. Nephrectomy still 
represents a significant factor that predicts for improved 
OS outcome in advanced RCC within population data-
bases such as SEER and NCDB. Median OS of  3 months 
in the non-CN group and that of  18 months for cases with 
CN suggests the large magnitude of  the disparity. Patient 
demographics and tumor characteristics make a significant 
impact on the incidence of  CN. The impact of  comorbid-
ities (number and type) appeared to be modest within 
the population represented in the Metropolitan Detroit 
SEER data and was not statistically significant. The opti-
mal management strategy of  patients with advanced RCC 
unable to undergo nephrectomy needs to be prospectively 
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Table 4: Metropolitan Detroit Distant Stage Kidney Cancer: 2000–2013 Odd Ratios for Likelihood of Nephrectomy.
Total
N 1008
Distribution
Nephr. Rate 
37 (%)
Adjusted OR 95% CI p-value
Age at Diagnosis (median 64)
(ref) Under 64 498 49 51 1.00
64 or Older 510 51 23 0.29 (0.21–0.39) <0.001
Sex
(ref) Female 338 34 36 1.00
Male 670 66 37 0.87 (0.64–1.19) 0.389
Race
(ref) Black 206 20 34 1.00
White 788 78 38 1.48 (1.03–2.13) 0.035
Other 14 1 36 -
Marital Status
(ref) Married 507 50 40 1.00
Divorced 118 12 31 0.60 (0.38–0.95) 0.031
Single 202 20 43 0.81 (0.56–1.19) 0.285
Widowed 146 14 21 0.51 (0.31–0.83) 0.006
Unknown 35 3 37 1.13 (0.52–2.44) 0.757
Insurance
(ref) Insured 663 66 38 1.00
Medicaid or Uninsured 277 27 40 1.12 (0.79–1.59) 0.524
Unknown or Missing 67 7 18 0.41 (0.21–0.81) 0.010
Histology
(ref) Clear Cell 695 69 34 1.00
Non-Clear Cell 313 31 45 1.68 (1.25–2.27) 0.001
Grade
(ref) Well or Mod Diff 75 7 44
left out of model because of the  
large proportion of unknowns
Poorly Diff 168 17 70
Undifferentiated 152 15 81
Unknown 613 61 16
Number of Comorbid conditions
(ref) None of the above 465 46 36 1.00
One 165 16 41 1.25 (0.84–1.87) 0.269
Two or more 156 15 46 1.76 (1.17–2.66) 0.007
Missing data 222 22 31 0.80 (0.54–1.18) 0.249
95% CI, 95% confidence interval; Mod Diff, moderately differentiated.
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Table 5: Metropolitan Detroit Distant Stage Kidney Cancer: 2000–2013 Survival Analysis by Nephrectomy Status for Demo-
graphic Characteristics and Comorbidities.
Total
N 
1008
Median Survival (months)
HR 95% CI p-valueNephr. 
19
No Nephr. 
5
Age at Diagnosis (median 64)
(ref) Under 64 551 22 5 1.00
64 or Older 553 15 5 1.08 (0.93–1.25) 0.335
Sex
(ref) Female 370 19 1.00
Male 734 20 1.00 (0.86–1.16) 0.990
Race (55 missing)
(ref) Black 232 30 4 1.00
White 857 18 5 1.02 (0.86–1.21) 0.824
Other 15 - - -
Marital Status
(ref) Married 552 18 5 1.00
Divorced 122 12 4 1.18 (0.95–1.46) 0.145
Single 222 43 4 0.76 (0.62–0.93) 0.007
Widowed 169 17 4 1.02 (0.82–1.25) 0.891
Unknown 39 16 8 0.71 (0.49–1.02) 0.064
Insurance
(ref) Insured 720 18 5 1.00
Medicaid or Uninsured 309 22 4 1.02 (0.86–1.22) 0.784
Unknown or Missing 75 31 4 1.35 (1.03–1.78) 0.032
Histology
(ref) Clear Cell 755 20 5 1.00
Non-Clear Cell 349 18.5 4 1.17 (1.01–1.36) 0.037
Grade
(ref) Well or Mod Diff 76 35 9 left out of model because of the large 
 proportion of unknowns
Poorly Diff 178 19 4
Undifferentiated 158 12 3
Unknown 692 36 5
Surgery
No Nephrectomy 726 - 3 1.00
Nephrectomy 378 19 - 0.40 (0.34–0.46) <0.001
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Table 5 (Continued): Metropolitan Detroit Distant Stage Kidney Cancer: 2000–2013 Survival Analysis by Nephrectomy Status 
for Demographic Characteristics and Comorbidities.
Total
N 
1008
Median Survival (months)
HR 95% CI p-valueNephr. 
19
No Nephr. 
5
Number of Comorbid conditions
(ref) None of the above 496 24 5 1.00
One 178 24 4 1.12 (0.92–1.36) 0.275
Two or more 169 18 5 1.10 (0.90–1.35) 0.370
Missing data 261 8.5 4 1.68 (1.39–2.01) <0.001
95% CI, 95% confidence interval; Mod Diff, moderately differentiated; Nephr, nephrectomy.
Figure 3:  (A) Overall survival noted in cases with nephrectomy correlated with missing, absence, and presence of comorbidities. 
(B) Overall survival seen in cases with no nephrectomy correlated with missing, absence, and presence of comorbidities.
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evaluated in future clinical trials, in the setting of  contem-
porary systemic therapy.
The subgroup of  synchronous primary and metastatic 
kidney cancer has been underrepresented in clinical trials. 
Future studies geared toward addressing the issues of  op-
timal efficacy of  therapy within this patient population are 
being planned. Patient and disease characteristics that de-
termine decision of  CN warrant further study and may rep-
resent a key to the enhancement of  outcomes in advanced 
renal cancer.
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